OS Therapies Achieves Incremental FDA Alignment Regarding Its Biologics License Application For OST-HER2 For Prevention Or Delay Of Recurrence In Fully-Resected, Pulmonary Metastatic Osteosarcoma
The Company aligned with the FDA on the use of the proposed adaptive design agreed upon with the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) for the
OS Therapies got the FDA's okay on their plan to test a new medicine. This means they can move forward with their study the way they designed it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.